Last reviewed · How we verify
BA3011
At a glance
| Generic name | BA3011 |
|---|---|
| Sponsor | Canadian Cancer Trials Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (PHASE2)
- CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC (PHASE2)
- CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |